By Product Insights

What made the Kadcyla Segment Dominant in the Antibody Drug Conjugates (ADC) Market in 2024?

The Kadcyla segment led the market due to its proven clinical effectiveness and widespread adoption for treating HER2-positive breast cancer. As one of the first FDA-approved antibody-drug conjugates, Kadcyla set a strong benchmark for targeted cancer therapy. Its ability to deliver potent anti-cancer agents directly to tumor cells with reduced side effects has driven its dominance, supported by increasing global demand and expanded therapeutic indications.

The Enhertu segment is expected to grow at the fastest CAGR due to its strong clinical success and expanding approvals across multiple cancer types, including breast, lung, and gastric cancers. Its innovative HER2-targeted antibody-drug conjugate design offers superior efficacy and improved patient outcomes. Rising global adoption, ongoing clinical trials exploring new indications, and strategic collaborations are boosting the market growth during the forecast period.

• For Instance, In January 2025, the U.S. approved Enhertu for treating unresectable or metastatic HR-positive, HER2-low or ultralow breast cancer, broadening its use to a larger patient group.
  

By Target Insights

Why the HER2 Segment Dominated the Antibody Drug Conjugates (ADC) Market in 2024?

The HER2 segment dominated the market in 2024 due to the high prevalence of HER2-positive cancers, particularly breast and gastric cancers, and the proven success of targeted therapies like Kadcyla and Enhertu. These HER2-directed ADCs have demonstrated strong clinical efficacy and safety, leading to widespread adoption. Continuous research, expanding treatment indications, and growing regulatory approvals further reinforced the dominance of the HER2 segment in the antibody-drug conjugate (ADC) market.

The CD22 segment is expected to grow at the fastest due to increasing use of CD22-targeted ADCs in treating hematologic cancer, especially B-cell malignancies like leukemia and lymphoma. These ADCs offer high specificity and effectiveness by directly targeting cancerous B-cells while minimizing harm to healthy cells. Rising clinical trials, strong research investments, and successful approvals of therapies such as lnotuzumab Ozogamicin are further propelling the rapid expansion of the CD22 segment.

By Technology Insights

What Made the Cleavable Segment Dominant in the Antibody Drug Conjugates (ADC) Market in 2024?

The cleavable segment held the highest market share in 2024 due to its superior ability to release cytotoxic drugs precisely at the tumor site, enhancing therapeutic efficacy while minimizing damage to healthy tissues. This technology enables better drug delivery control and improved safety profiles, making it widely preferred in ADC development. Its proven success in several approved ADCs and ongoing advancements in linker chemistry have further strengthened its dominance in the market.

The non-cleavable segment is expected to grow at the fastest CAGR due to its enhanced stability to deliver cytotoxic payloads directly within target cancer cells, reducing premature drug release. This technology provides improved safety and prolonged circulation time, leading to better treatment outcomes. Growing research on next-generation ADCs and rising preference for stable linkers in oncology drug development are driving the rapid expansion of the non-cleavable segment during the forecast period.

By Regional Analysis

How is North America contributing to the Expansion of the Antibody Drug Conjugates (ADC) Market?

North America dominated the market in 2024 due to the strong presence of leading biopharmaceutical companies, advanced healthcare infrastructure, and high investment in oncology research. Favorable regulatory support from the FDA and early adoption of innovative cancer therapies further fueled market growth. Additionally, rising cancer prevalence, increasing clinical trials, and the availability of approved ADCs such as Kadcyla and Enhertu contributed to North America's leading revenue share in the global market.

How is Asia-Pacific Accelerating the Antibody Drug Conjugates (ADC) Market?

Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to rising cancer incidence, improving healthcare infrastructure, and increasing access to advanced treatments. Growing investments in biopharmaceutical research, expanding clinical trials, and supportive government initiatives are driving ADC adoption. Additionally, collaborations between global and regional pharmaceutical companies and rising awareness of targeted cancer therapies are boosting market growth across major countries like China, Japan, South Korea, and India.

Antibody Drug Conjugates Market Top Key Companies:

The following are the leading companies in the antibody drug Conjugates market. These companies collectively hold the largest market share and dictate industry trends.

• Seagen, Inc.
• Takeda Pharmaceutical Company Ltd.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• Daiichi Sankyo Company Ltd.
• GlaxoSmithKline Plc
• Astellas Pharma, Inc.
• ADC Therapeutics SA

Recent Developments in the Antibody Drug Conjugates (ADC) Market

• In June 2024, Adcytherix SAS was founded and raised €30 million in seed funding to develop innovative antibody-drug conjugates (ADCs) aimed at addressing unmet needs in cancer treatment.
• In January 2024, MediLink Therapeutics partnered with F. Hoffmann-La Roche Ltd. through a licensing and collaboration agreement to develop YL211, an advanced next-generation antibody-drug conjugate (ADC).

More Insights in Nova One Advisor:

• Europe Dental Services Market - The Europe dental services market size
• AI in Life Sciences Market - The global artificial intelligence (AI) in life sciences market
• Dental Implants Market - The global dental implants market size
• Targeted DNA RNA Sequencing Market - The global targeted DNA RNA sequencing market
• U.S. Dental Services Market - The US dental services market size
• U.S. Livestock Monitoring Market - The U.S. livestock monitoring market size
• In Vitro Fertilization (IVF) Services Market - The global in vitro fertilization (IVF) services market size
• Life Sciences IT Market - The global life sciences IT market size
• U.S. Humidifiers Market - The U.S. humidifiers market size
• Digital Manufacturing in Life Sciences Market - The global digital manufacturing in life sciences market size
• Middle East AI In Patient Engagement Market - The Middle East patient engagement solutions market size
• Middle East Cosmetic Surgery & Procedure Market - The Middle East cosmetic surgery and procedure market size

Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Antibody Drug Conjugates market.

By Application

• Blood Cancer
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer
  

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others
  

By Target

• HER2
• CD22
• CD30
• Others

By Technology

• Type
  • Cleavable Linker
  • Non-cleavable Linker
  • Linkerless
• Linker Technology Type
  • VC
  • Sulfo-SPDB
  • VA
  • Hydrazone
  • Others
• Payload Technology
  • MMAE
  • MMAF
  • DM4
  • Camptothecin
  • Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)
  

About-Us

Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.

Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.

Our Trusted Data Partners

Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics | Towards Chem and Material

Web:

Contact Us

USA: +1 804 420 9370

Email: ...

For Latest Update Follow Us: LinkedIn